Click here to close now.




















Welcome!

News Feed Item

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

LONDON, Feb. 17, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024

Report Details

Needle-free injecting technologies - discover activities, developments, and prospects of leading companies

What does the future hold for makers of needle-free injection (NFI) products? See what's possible. Visiongain's updated report shows you data to 2024 for that industry and market. There you find analysis, trends, opportunities, and forecasting of revenues.

Our study analyses 14 leading developers and producers of those medical devices. You can now explore the future of NFI to introduce drugs, finding its potential. Discover how you can benefit.

Forecasts and other data for staying ahead in knowledge of those medical injectors

There you examine the industry for needleless injection and needle-free syringes - insulin injectors and other systems. Find what's happening. Potential exists for novel and improved subcutaneous, intradermal, intramuscular, and intravenous drug delivery.

That industry advances. In our report you assess product ranges, historical data, R&D, market shares, sales predictions, and growth rates. There you get quantitative and qualitative analyses. You also find 42 tables, 17 charts and three research interviews.

NFI technology - discover how to help your work, also finding where money lies

Avoid missing out. See how developers overcome problems with parenteral drug application, esp. benefiting use of biological drugs (biologics). You also discover potential revenues.

So the following sections outline what you get in our investigation.

Companies based in North America - what're their outlooks?

First our study gives you financial data and discussions for prominent North American NFI developers and manufacturers:
• Antares Pharma
• Bioject Medical Technologies
• Zogenix
• Activa
• D'Antonio Consultants International.

You also find profiles of these organisations:
• National Medical Products
• Medical International Technologies
• Penjet Corporation
• PharmaJet
• Valeritas.

Discover what the present and future hold for those companies. Also find the money. See revenue predictions to 2024 for the overall world industry for needle-free injection devices.

Hear, too, about developments and prospects of competitors in other countries.

Europe - outlooks for leading developers and producers of medical injection technology

Next our report analyses European-based specialists in that drug delivery:
• Akra Dermojet
• Crossject Medical Technology
• Injex Pharma
• Glide Pharma.

Many commercial opportunities exist, with expanding revenues possible this decade. Discover the best potentials. You find how companies gain advantages and raise sales.

In that work you see what affects the future - what influences success.

Events and forces for developing, producing, marketing, and selling NFI technologies

Our study explains issues affecting that industry and market from 2013 onwards, including these:
• Applications - pain management, vaccine delivery, treating diabetes, paediatric medicine, and other therapies
• Regulations in the US and Europe
• Developments stimulating and restraining that market, inc. allied and competing products.

You also investigate these forces:
• Jet injector devices, transdermal patches, microneedles, pen injectors, and other therapeutic systems
• Solid formulations and other challenges, innovations, and progress in therapy
• Deals, collaborations, and other changes affecting that sector.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Examine what stimulates and restrains that industry and market.

You discover, then, what the present and future hold. You also read opinions from our survey of companies. Stay ahead for information.

Ways Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024 helps you

In particular, our report gives you the following knowledge:
• Profiles of 14 leading companies - assess products, strategies, and results
• Competition and opportunities - explore what affects the needle-free injectors industry, finding what influences its sales and determines its future
• Revenues to 2024 for that market at world level - discover prospects for success.

That work helps people interested in the future of pharmaceuticals and related instruments, containers, and accessories.

Analysis found nowhere else - discover the future of those devices and applications

Our work gives independent analysis. There you receive business intelligence found only in our report. You're free to choose, and our work lets you discover where the money lies.

With that investigation you're less likely to fall behind in information or miss opportunity. See there how you could benefit your research, analysis, and decisions. So avoid missing out.

Also find how you could save time and get recognition for insight, raising your influence.

1. Executive Summary

1.1 Leading NFI Device Manufacturers: Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
1.4 Aims, Scope and Format of the Report
1.5 Glossary of Terms

2. Introduction to Needle-Free Injection

2.1 What is Needle-Free Drug Delivery?
2.1.1 History of Needle-Free Injections: From Military to Clinic
2.1.2 Modern Needle-Free Devices: Concept of High Pressure Fluid Jet
2.2 What is the Rationale for Needle-Free Injections?
2.3 Applications of Needle-Free Drug Delivery
2.3.1 Pain Management: Using NFI Devices to Administer Lidocaine
2.3.2 Vaccine Delivery: Improving Immune Response
2.3.3 Insulin Delivery: Jet Injection Enhances Drug Distribution
2.3.4 Paediatrics: Alleviating Childhood Anxiety and Phobia
2.4 Regulation of Needle-Free Delivery Devices
2.4.1 The US Regulation System: Prolonged Approval Process
2.4.2 The European Regulation System: Manufacturers Seeking EU Approval First?
2.5 Advantages and Disadvantages of Needle-Free Systems

3. The Global Needle-Free Injection Device Market, 2013-2024

3.1 The Global Needle-Free Injection Device Market, 2012
3.2 The Global Needle-Free Injection Device Market: Revenue Forecast, 2013-2024
3.3 How Will the Market Shares of Leading Sectors Change From 2013-2024?
3.4 What Will Drive the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.5 What Factors are Likely to Restrain the Global Needle-Free Injection Device Market Between 2014 and 2024?
3.6 The Global Jet Injector Device Market, 2012
3.6.1 The Global Jet Injector Device Market: Revenue Forecast, 2013-2024
3.6.2 The Global Jet Injector Device Market: Industry Trends, 2013-2024
3.7 The Global Competing Technologies Market, 2012
3.7.1 The Global Competing Technologies Market: Revenue Forecast, 2013-2024
3.7.2 The Global Competing Technologies Market: Industry Trends, 2013-2024
3.7.2.1 Transdermal Patches: Attractive and Cheap Option
3.7.2.2 Microneedle Technology: Huge Potential for Mass Vaccinations
3.7.2.3 Metered Dose Inhalers: Change in Device Propellant to Drive Adoption

4. The Leading North American Needle-Free Injection Device Manufacturers, 2013

4.1 Antares Pharma
4.1.1 Needle-Free Products
4.1.1.1 Vision™: Delivering Liquid Insulin or Human Growth Hormone
4.1.1.2 Vibex™: Hidden Needle to Alleviate Patient Fear
4.1.1.3 Pen Injector: Devices Being Used Clinical Testing
4.1.2 Sales Performance, 2012
4.1.3 Needle-Free Injection Device Pipeline
4.1.3.1 Vibex™ MTX: Targeting Growing Population of RA Sufferers
4.1.3.2 Vibex™ QS (QuickShot): Modified Vibex to Offer Improved Function
4.1.3.3 OTREXUP™: Combining Vibex MTX and Methotrexate
4.2 Bioject Medical Technologies
4.2.1 Needle-Free Products
4.2.1.1 Biojector® 2000: Adaptable Power Source Allows Use in Home and Mass Vaccination Setting
4.2.1.2 Vitajet™: Low-cost Insulin Delivery System
4.2.1.3 ZetaJet™: Auto-disable Feature Improves User Safety
4.2.2 Sales Performance
4.2.3 Needle-Free Injection Device Pipeline
4.2.3.1 Intradermal Pen Injector: Targeted Drug Delivery
4.2.3.2 Iject®: Providing Tailored Depth of Penetration
4.2.3.3 Jupiter Jet: Multi Dosing With Single Loaded Syringe
4.2.4 Collaborations
4.2.4.1 MPI Research: Seeking Drug/Device Combinations
4.2.4.2 World Health Organisation (WHO): the Push to Eradicate Infectious Disease in Developing Countries
4.3 Zogenix
4.3.1 Needle-Free Products
4.3.1.1 Sumavel® DosePro®: Rapid Acting Migraine Relief
4.3.2 Sales Performance, 2012
4.3.3 Needle-Free Injection Device Pipeline
4.3.3.1 Relday™: Needle-based Alterative for Improved Drug Distribution
4.3.4 Collaborations
4.3.5 Manufacturing
4.4 Activa Brand Products, Inc.
4.4.1 Technology: the Activa Family for Diabetics
4.4.2 Needle-Free Products
4.4.2.1 Product Advantages
4.5 D'Antonio Consultants International Inc. (DCI)
4.5.1 Needle-Free Products
4.5.1.1 LectraJet®: Lightweight Device Reduces User Fatigue
4.5.2 Needle-Free Injection Device Pipeline
4.5.2.1 Low Workload Jet Injector: Single-shot Manuel System
4.5.2.2 Multi Channel Jet Injector: For Simultaneous Vaccine Delivery
4.6 National Medical Products, Inc.
4.6.1 Needle-Free Products
4.6.1.1 J-Tip®: Offering Needle-free Administration of Anaesthesia
4.7 Medical International Technologies
4.7.1 Needle-Free Products
4.7.1.1 MED-JET®: Extremely Thin Orifice Offers Improved Drug Absorption
4.7.2 Sales Performance, 2012
4.7.3 Increased Awareness Through Globalisation
4.8 Penjet Corporation
4.8.1 Needle-Free Products
4.8.1.1 Penjet®: Nitrogen-powered Device Allows Efficient Storage
4.8.2 Applications
4.8.2.1 Multi-Component Drugs
4.8.2.2 Lyophilised Drug Delivery
4.8.2.3 Small Pox Vaccination
4.9 PharmaJet
4.9.1 Needle-Free Products
4.9.1.1 STRATIS®: Drug Delivery in Less Than a Second
4.9.2 Applications
4.9.3 Collaborations: Pursuing a Drug/Device Combination for Vaccine Administration
4.10 Valeritas
4.10.1 Needle-Free Products
4.10.1.1 Mini-Ject™: Potential Delivery of Lyophilised Drugs May Open Huge Opportunities for Valeritas

5. The Leading European Needle-Free Injection Device Manufacturers, 2013

5.1 Akra Dermojet
5.1.1 Needle-Free Products
5.1.1.1 Dermojet® "HR": User-Friendly Design Allows Use in High Intensive Applications
5.1.1.2 DERMOJET Polymedical®: Interchangeable Injection Tips Reduces Risk of Contamination
5.1.1.3 Automatic DERMOJET®
5.2 Crossject Medical Technology
5.2.1 Technology: Highly Customisable Device Allows Tailoring to Specific Drugs
5.2.2 Needle-Free Products
5.2.2.1 Zeneo®: Gas Propellant Generated Upon Injection
5.3 Injex Pharma AG
5.3.1 Needle-Free Products
5.3.1.1 INJEX30®: First Multiple Application Needle-Free Device?
5.4 Glide Pharma
5.4.1 Needle-Free Products
5.4.1.1 Glide SDI®
5.4.1.2 Applications
5.4.2 Advantages
5.4.2.1 Injecting Solid Formulations
5.4.2.2 Pharmaceutical Companies
5.4.3 Collaboration with Pfenex Inc. To Aid Delivery of Solid Dose Vaccine

6. Qualitative Analysis of the Global Needle-Free Injection Device Market, 2013-2024

6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.1.1 Strengths
6.1.1.1 A Less Painful Alternative to Needle-Based Injections
6.1.1.2 No Specialist Training Required for Delivery
6.1.1.3 Reduced Transport Costs
6.1.2 Weaknesses
6.1.2.1 Expensive Technology
6.1.2.2 Inefficient Manufacturing Process
6.1.2.3 Off Patent/Generics Require Reformulating Prior to Use in Needle-Free Delivery Systems
6.1.3 Opportunities
6.1.3.1 Emerging Economies
6.1.3.2 Mass Immunisation Programmes
6.1.3.3 Potential Delivery of Vaccines
6.1.3.4 Patent Expiry of Leading Drugs will Increase Competition
6.1.4 Threats
6.1.4.1 Traditional Needles and Syringes are Cheap to Mass Produce
6.1.4.2 Limited Clinical Data
6.1.4.3 Increased Scrutiny from Regulatory Bodies
6.1.4.4 Medical Device Excise Tax
6.2 STEP Analysis of the Global Needle-Free Injection Device Market, 2013-2024
6.2.1 Social Factors
6.2.2 Technological Developments
6.2.3 Economical Pressures
6.2.4 Political Issues

7. Opinions from Our Industry Survey

7.1 Interview with Zogenix Technologies
7.1.1 Recent Technological Developments in Needle-Free Systems
7.1.2 Competing Technologies and Market Opportunities
7.1.3 Market Restraints and Future Directions
7.2 Interview with Bioject Medical Technologies
7.2.1 Finding a Competitive Edge over Market Rivals
7.2.2 Market Dynamics and Company Collaborations
7.2.3 Potential of Emerging Markets and Regulatory Concerns
7.3 Interview with Team Consulting
7.3.1 Historical Development of the Needle-Free Market
7.3.2 Company Activities and Overcoming the Skin Barrier
7.3.3 Challenges and Limits to Market Growth
7.3.4 Prospects for the Needle-Free Market

8. Conclusions

8.1 The Global Needle-Free Injection Device Market, 2013-2024
8.2 Zogenix Dominated the Global Needle-Free Injection Device Market in 2012
8.3 Strong Company Pipeline Will Help Drive the Market
8.4 Concluding Remarks

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Examples of Needle-Free Vaccine Delivery Systems, 2013
Table 2.2 Examples of Needle-Free Insulin Delivery Systems, 2013
Table 2.3 Advantages and Disadvantages of Needle-Free Injection, 2013
Table 3.1 The Global Needle Free Injection Device Market: Revenue ($m) and Market Share (%) by Technology, 2012
Table 3.2 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) by Technology, 2013-2024
Table 3.3 The Global Needle-Free Injection Device Market: Market Share (%) by Technology, 2013-2024
Table 3.4 The Global Needle-Free Injection Device Market: Drivers and Restraints, 2013-2024
Table 3.5 Patent Expiries for Leading Drugs, 2014-2016
Table 3.6 Classification of Jet Injector Devices, 2013
Table 3.7 The Global Jet Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.8 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.9 Insulin Inhalation Systems in Development, 2013
Table 3.10 Vaccine Inhalers in Development, 2013
Table 4.1 Antares Pharma: Key Facts, 2013
Table 4.2 Antares Pharma Licensing Partnerships, 2013
Table 4.3 Antares Pharma: Revenue ($m) & Revenue Share (%) by Business Segment, 2012
Table 4.4 Antares Pharma: Product Revenue ($m, CAGR %) by Category, 2010-2012
Table 4.5 Bioject Medical Technologies: Key Facts, 2013
Table 4.6 Bioject: Revenue ($m) and Revenue Share (%), by Product Line, 2010
Table 4.7 Bioject: Summary of Technologies
Table 4.8 Zogenix: Key Facts, 2013
Table 4.9 Zogenix: Summary of Technology
Table 4.10 Zogenix: Revenue ($m) and Revenue Share (%) by Business Segment, 2012
Table 4.11 Activa Brand Products: Key Facts, 2013
Table 4.12 D'Antonio Consultants: Key Facts, 2013
Table 4.13 National Medical Products: Key Facts, 2013
Table 4.14 Medical International Technologies: Key Facts, 2013
Table 4.15 Medical International Technologies: Revenue ($m, CAGR %), 2009-2012
Table 4.16 PenJet Corporation: Key Facts, 2013
Table 4.17 PharmaJet: Key Facts, 2013
Table 4.18 Valeritas: Key Facts, 2013
Table 5.1 Akra Dermojet: Key Facts, 2013
Table 5.2 Akra Dermojet: Summary of Technology
Table 5.3 Crossject Medical Technology: Key Facts, 2013
Table 5.4 Injex Pharma AG: Key Facts, 2013
Table 5.5 Glide Pharma: Key Facts, 2013
Table 6.1 SWOT Analysis of the Global Needle-Free Injection Device Market, 2013-2024
Table 6.2 Average Price for Needle-Free Drug/Vaccine Delivery Technology, 2013
Table 6.3 Patent Expiries for Leading Drugs, 2014-2016
Table 6.4 The Global Needle-Free Injection Market: STEP Analysis, 2013-2024
Table 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m, AGR %, CAGR %) and Market Share (%) by Technology, 2012, 2015, 2018, 2021 and 2024

List of Figures

Figure 3.1 The Global Needle Free Injection Device Market: Share (%) by Technology, 2012
Figure 3.2 The Global Needle Free Injection Device Market: Revenue ($m) by Technology, 2012
Figure 3.3 The Global Needle-Free Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.4 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2018
Figure 3.5 The Global Needle-Free Injection Device Market: Share (%) by Technology, 2024
Figure 3.6 The Global Jet Injection Device Market: Revenue Forecast ($m), 2013-2024
Figure 3.7 The Global Competing Needle-Free Technologies Market: Revenue Forecast ($m), 2013-2024
Figure 4.1 Antares Pharma: Revenue Share (%) by Business Segment, 2012
Figure 4.2 Antares Pharma: Product Revenue ($m) by Category, 2010-2012
Figure 4.3 Bioject: Revenue Share (%) by Product Line, 2010
Figure 4.4 Bioject: Revenue ($m), 2010-2012
Figure 4.5 Zogenix: Revenue Share (%) by Business Segment, 2012
Figure 4.6 Zogenix: Revenue ($m) by Business Segment, 2010-2012
Figure 4.7 Medical International Technologies: Revenue ($m), 2009-2012
Figure 6.1 The Transport Process for a Vaccine
Figure 8.1 The Global Needle-Free Injection Device Market: Revenue Forecast ($m) by Technology, 2012, 2015, 2018, 2021 and 2024
Figure 8.2 The Global Needle-Free Injection Device Market: Leading Companies by Revenue ($m), 2012

Companies Listed

3M
Actavis
Activa Brand Products
Aerogen
Akra Dermojet
ALZA Pharmaceuticals
Ankara University
Antares Pharma
Aradigm Corporation
Astellas Pharma
AstraZeneca
Battelle
Bill and Melinda Gates Foundation
Bioject Medical Technologies
BioValve Technologies
Bristol-Myers Squibb
Cambridge Consultants
CDC Measles Eradication Committee
Centre for Devices and Radiological Health (CDRH)
Centre for Disease Control and Prevention (CDC)
China State Food and Drug Administration (SFDA)
Covidien
Crossject Medical Technology
CSL Behring
CSL Limited
Daewoong Pharmaceuticals
Dance Pharmaceuticals
D'Antonio Consultants International
Diabetes Management International
Dr. Reddy's Laboratories
Durect Corporation
Echo Therapeutics
Eli Lilly
Eurojet Medical
European Union
Ferndale Pharma Group
Ferring Pharmaceuticals
Food and Drug Administration (FDA)
Georgia Tech University
GlaxoSmithKline (GSK)
Glide Pharma
Harvard University
Injex Pharma AG
JCR Pharmaceuticals
Jiangsu Hualan Medical International Technologies
Johnson & Johnson
Mallinckrodt Pharmaceuticals
MannKind
Meda Pharmaceuticals
Medical International Technologies
MedImmune
Merck & Co.
Merck Serono
Mglas AG
Minnesota Rubber and Plastics (MRP)
MPI Research
Mylan
National Medical Products
Nektar Therapeutics
North Carolina University
Novartis
Novo Nordisk
Nypro Limited
Patheon
Penjet Corporation
Pfenex Inc.
Pfizer
PharmaJet
Philips Medical
Sanofi-Aventis
Sanofi-Pasteur
Takeda
Team Consulting
Teva Pharmaceuticals
UCB
University of Colorado
US Army Medical Research Institute of Infectious Disease (USAMRIID)
Valeritas
Vaxxas
Weston Medical
World Health Organization (WHO)
Zogenix
Zomajet
Zosano Pharma

Read the full report:
Medical Device Leader Series: Top Needle-Free Injection Device Manufacturers 2014-2024
http://www.reportbuyer.com/pharma_healthcare/medical_devices/medical_device_leader_series_top_needle_free_injection_device_manufacturers.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]  
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that HPM Networks will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. For 20 years, HPM Networks has been integrating technology solutions that solve complex business challenges. HPM Networks has designed solutions for both SMB and enterprise customers throughout the San Francisco Bay Area.
Chuck Piluso presented a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. Prior to Secure Infrastructure and Services, Mr. Piluso founded North American Telecommunication Corporation, a facilities-based Competitive Local Exchange Carrier licensed by the Public Service Commission in 10 states, serving as the company's chairman and president from 1997 to 2000. Between 1990 and 1997, Mr. Piluso served as chairman & founder of International Te...
The Software Defined Data Center (SDDC), which enables organizations to seamlessly run in a hybrid cloud model (public + private cloud), is here to stay. IDC estimates that the software-defined networking market will be valued at $3.7 billion by 2016. Security is a key component and benefit of the SDDC, and offers an opportunity to build security 'from the ground up' and weave it into the environment from day one. In his session at 16th Cloud Expo, Reuven Harrison, CTO and Co-Founder of Tufin,...
Container technology is sending shock waves through the world of cloud computing. Heralded as the 'next big thing,' containers provide software owners a consistent way to package their software and dependencies while infrastructure operators benefit from a standard way to deploy and run them. Containers present new challenges for tracking usage due to their dynamic nature. They can also be deployed to bare metal, virtual machines and various cloud platforms. How do software owners track the usag...
SYS-CON Events announced today that MobiDev, a software development company, will exhibit at the 17th International Cloud Expo®, which will take place November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. MobiDev is a software development company with representative offices in Atlanta (US), Sheffield (UK) and Würzburg (Germany); and development centers in Ukraine. Since 2009 it has grown from a small group of passionate engineers and business managers to a full-scale mobi...
With SaaS use rampant across organizations, how can IT departments track company data and maintain security? More and more departments are commissioning their own solutions and bypassing IT. A cloud environment is amorphous and powerful, allowing you to set up solutions for all of your user needs: document sharing and collaboration, mobile access, e-mail, even industry-specific applications. In his session at 16th Cloud Expo, Shawn Mills, President and a founder of Green House Data, discussed h...
For IoT to grow as quickly as analyst firms’ project, a lot is going to fall on developers to quickly bring applications to market. But the lack of a standard development platform threatens to slow growth and make application development more time consuming and costly, much like we’ve seen in the mobile space. In his session at @ThingsExpo, Mike Weiner, Product Manager of the Omega DevCloud with KORE Telematics Inc., discussed the evolving requirements for developers as IoT matures and conducte...
There are many considerations when moving applications from on-premise to cloud. It is critical to understand the benefits and also challenges of this migration. A successful migration will result in lower Total Cost of Ownership, yet offer the same or higher level of robustness. In his session at 15th Cloud Expo, Michael Meiner, an Engineering Director at Oracle, Corporation, analyzed a range of cloud offerings (IaaS, PaaS, SaaS) and discussed the benefits/challenges of migrating to each offe...
One of the hottest areas in cloud right now is DRaaS and related offerings. In his session at 16th Cloud Expo, Dale Levesque, Disaster Recovery Product Manager with Windstream's Cloud and Data Center Marketing team, will discuss the benefits of the cloud model, which far outweigh the traditional approach, and how enterprises need to ensure that their needs are properly being met.
In their session at 17th Cloud Expo, Hal Schwartz, CEO of Secure Infrastructure & Services (SIAS), and Chuck Paolillo, CTO of Secure Infrastructure & Services (SIAS), provide a study of cloud adoption trends and the power and flexibility of IBM Power and Pureflex cloud solutions. In his role as CEO of Secure Infrastructure & Services (SIAS), Hal Schwartz provides leadership and direction for the company.
In a recent research, analyst firm IDC found that the average cost of a critical application failure is $500,000 to $1 million per hour and the average total cost of unplanned application downtime is $1.25 billion to $2.5 billion per year for Fortune 1000 companies. In addition to the findings on the cost of the downtime, the research also highlighted best practices for development, testing, application support, infrastructure, and operations teams.
"We've just seen a huge influx of new partners coming into our ecosystem, and partners building unique offerings on top of our API set," explained Seth Bostock, Chief Executive Officer at IndependenceIT, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
Mobile, social, Big Data, and cloud have fundamentally changed the way we live. “Anytime, anywhere” access to data and information is no longer a luxury; it’s a requirement, in both our personal and professional lives. For IT organizations, this means pressure has never been greater to deliver meaningful services to the business and customers.
The Internet of Everything (IoE) brings together people, process, data and things to make networked connections more relevant and valuable than ever before – transforming information into knowledge and knowledge into wisdom. IoE creates new capabilities, richer experiences, and unprecedented opportunities to improve business and government operations, decision making and mission support capabilities.
Puppet Labs has announced the next major update to its flagship product: Puppet Enterprise 2015.2. This release includes new features providing DevOps teams with clarity, simplicity and additional management capabilities, including an all-new user interface, an interactive graph for visualizing infrastructure code, a new unified agent and broader infrastructure support.